Liquidia (NASDAQ:LQDA) Posts Earnings Results

Liquidia (NASDAQ:LQDA) posted its earnings results on Wednesday. The company reported ($0.46) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.08), Zacks reports. Liquidia had a negative return on equity of 163.21% and a negative net margin of 765.38%. The business had revenue of $2.92 million during the quarter, compared to the consensus estimate of $4.60 million.

Liquidia Stock Up 3.5 %

Liquidia stock opened at $15.44 on Friday. The firm has a market cap of $1.31 billion, a P/E ratio of -9.47 and a beta of 0.07. The business has a fifty day moving average of $14.73 and a two-hundred day moving average of $12.14. Liquidia has a twelve month low of $8.26 and a twelve month high of $16.99.

Insider Transactions at Liquidia

In related news, General Counsel Russell Schundler sold 16,393 shares of the company’s stock in a transaction on Tuesday, January 14th. The stock was sold at an average price of $11.78, for a total value of $193,109.54. Following the transaction, the general counsel now directly owns 573,478 shares of the company’s stock, valued at $6,755,570.84. This represents a 2.78 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Roger Jeffs sold 22,343 shares of the stock in a transaction dated Tuesday, January 14th. The shares were sold at an average price of $11.78, for a total value of $263,200.54. Following the completion of the transaction, the chief executive officer now directly owns 1,019,177 shares in the company, valued at $12,005,905.06. This represents a 2.15 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 71,245 shares of company stock valued at $843,326 in the last 90 days. Insiders own 30.10% of the company’s stock.

Analyst Ratings Changes

LQDA has been the topic of several analyst reports. Wells Fargo & Company began coverage on Liquidia in a research note on Friday, December 20th. They set an “overweight” rating and a $20.00 price objective on the stock. Scotiabank increased their price target on Liquidia from $30.00 to $34.00 and gave the company a “sector outperform” rating in a report on Thursday. Needham & Company LLC raised their price target on Liquidia from $19.00 to $25.00 and gave the stock a “buy” rating in a research report on Thursday. Finally, HC Wainwright reiterated a “buy” rating and set a $29.00 price objective on shares of Liquidia in a research report on Thursday. One analyst has rated the stock with a hold rating, six have given a buy rating and two have issued a strong buy rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus target price of $26.63.

About Liquidia

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).